Northern Japan Art Museum Finally Reopens After 2 Years; Akita Ranga Art to be Showcased Year-Round at Museum

The entrance of Akita Senshu Museum of Art in Akita City on June 29
13:21 JST, July 17, 2024
AKITA — The Akita Senshu Museum of Art has finally reopened after two years, and a ceremony was held on June 29 to celebrate the occasion.
The museum in Akita City opened in 1989 and had been undergoing renovations due to its aging structure since June 2022. The renovations cost approximately ¥1.426 billion.
Lighting fixtures were changed from fluorescent lights to LEDs, and wood was used for the floors and stairs to create a warmer atmosphere. Two of the four exhibition rooms were combined, and a new space was created to showcase Akita Ranga, which are Western-influenced works painted by samurai from the Akita domain during the mid-Edo period (1603-1867), year-round.
“We have created an environment where visitors can enjoy the works more beautifully than ever before,” said Mayor Motomu Hozumi at the ceremony. “We will strive to help create a lively downtown area.”
The first special exhibition after reopening is “Iittala: Stars of Finnish Glass,” which features Finnish tableware brand products. The exhibition will run until Aug. 25.
Related Tags
Top Articles in Features
-
Tokyo’s New Record-Breaking Fountain Named ‘Tokyo Aqua Symphony’
-
High-Hydration Bread on the Rise, Seeing Increase in Specialty Shops, Recipe Searches
-
Japanese Students Use Traditional Pickle to Create Novel Wagashi Confectionery
-
Heirs to Kyoto Talent: Craftsman Works to Keep Tradition of ‘Kinran’ Brocade Alive Through Initiatives, New Creations
-
My Spendthrift Mother Constantly Asks Me for Money
JN ACCESS RANKING
-
Producer Behind Pop Group XG Arrested for Cocaine Possession
-
Japan PM Takaichi’s Cabinet Resigns en Masse
-
Man Infected with Measles Reportedly Dined at Restaurant in Tokyo Station
-
Videos Plagiarized, Reposted with False Subtitles Claiming ‘Ryukyu Belongs to China’; Anti-China False Information Also Posted in Japan
-
iPS Treatments Pass Key Milestone, but Broader Applications Far from Guaranteed

